BUZZ — Australia's Mesoblast rises on FDA approval for new potency assay for commercial Ryoncil

* Shares of Mesoblast rise as much as 5.1% to A$2.29, their biggest intraday pct gain since August 28 * Shares hit their highest level since September 9 * The biotech company gets US FDA approval to implement new potency assay for release and stability monitoring of all new commercial products of Ryoncil, its mesenchymal stromal cell product * Ryoncil is for the treatment of steroid-refractory acute graft versus host disease * YTD, Mesoblast stock down 17.7% (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com)